Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT
Phase of Trial: Phase I
Latest Information Update: 21 Mar 2018
Price : $35 *
At a glance
- Drugs Sonidegib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 21 Mar 2017 Status changed from recruiting to discontinued.
- 08 May 2014 New trial record
- 14 Apr 2014 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.